8RVE
| Vimentin intermediate filament | Descriptor: | Vimentin | Authors: | Eibauer, M, Medalia, O. | Deposit date: | 2024-02-01 | Release date: | 2024-04-10 | Last modified: | 2024-07-03 | Method: | ELECTRON MICROSCOPY (7.2 Å) | Cite: | Vimentin filaments integrate low-complexity domains in a complex helical structure. Nat.Struct.Mol.Biol., 31, 2024
|
|
4GH7
| |
4AEL
| PDE10A in complex with the inhibitor AZ5 | Descriptor: | 2-(2'-ETHOXYBIPHENYL-4-YL)-4-HYDROXY-1,6-NAPHTHYRIDINE-3-CARBONITRILE, CAMP AND CAMP-INHIBITED CGMP 3', 5'-CYCLIC PHOSPHODIESTERASE 10A, ... | Authors: | Bauer, U, Giordanetto, F, Bauer, M, OMahony, G, Johansson, K.E, Knecht, W, Hartleib-Geschwindner, J, Toppner Carlsson, E, Enroth, C, Sjogren, T. | Deposit date: | 2012-01-11 | Release date: | 2012-01-25 | Last modified: | 2023-12-20 | Method: | X-RAY DIFFRACTION (2.2 Å) | Cite: | Discovery of 4-Hydroxy-1,6-Naphthyridine-3-Carbonitrile Derivatives as Novel Pde10A Inhibitors. Bioorg.Med.Chem.Lett., 22, 2012
|
|
2MBK
| The Clip-segment of the von Willebrand domain 1 of the BMP modulator protein Crossveinless 2 is preformed | Descriptor: | Crossveinless 2 | Authors: | Mueller, T.D, Fiebig, J.E, Weidauer, S.E, Qiu, L, Bauer, M, Schmieder, P, Beerbaum, M, Zhang, J, Oschkinat, H, Sebald, W. | Deposit date: | 2013-08-02 | Release date: | 2013-10-16 | Last modified: | 2023-06-14 | Method: | SOLUTION NMR | Cite: | The Clip-Segment of the von Willebrand Domain 1 of the BMP Modulator Protein Crossveinless 2 Is Preformed. Molecules, 18, 2013
|
|
6ZLE
| |
6ZPR
| Solution structure of MLKL executioner domain in complex with a covalent inhibitor | Descriptor: | 7-(2-methoxyethoxymethyl)-1,3-dimethyl-purine-2,6-dione, Mixed lineage kinase domain-like protein,Mixed lineage kinase domain-like protein | Authors: | Ruebbelke, M, Bauer, M, Hamilton, J, Binder, F, Nar, H, Zeeb, M. | Deposit date: | 2020-07-09 | Release date: | 2020-12-16 | Last modified: | 2021-01-06 | Method: | SOLUTION NMR | Cite: | Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
7NM5
| Solution structure of MLKL executioner domain in complex with a fragment | Descriptor: | 2-[(~{S})-methoxy-(4-phenylphenyl)methyl]-3~{H}-benzimidazole-5-carboxylic acid, Mixed lineage kinase domain-like protein | Authors: | Ruebbelke, M, Bauer, M, Hamilton, J, Binder, F, Nar, H, Zeeb, M. | Deposit date: | 2021-02-23 | Release date: | 2021-09-22 | Last modified: | 2024-06-19 | Method: | SOLUTION NMR | Cite: | Discovery and Structure-Based Optimization of Fragments Binding the Mixed Lineage Kinase Domain-like Protein Executioner Domain. J.Med.Chem., 64, 2021
|
|
7NM2
| Solution structure of MLKL executioner domain in complex with a fragment | Descriptor: | 2-[(~{S})-methoxy-(4-propan-2-ylphenyl)methyl]-3~{H}-benzimidazole-5-carboxylic acid, Mixed lineage kinase domain-like protein | Authors: | Ruebbelke, M, Bauer, M, Hamilton, J, Binder, F, Nar, H, Zeeb, M. | Deposit date: | 2021-02-23 | Release date: | 2021-09-22 | Last modified: | 2024-06-19 | Method: | SOLUTION NMR | Cite: | Discovery and Structure-Based Optimization of Fragments Binding the Mixed Lineage Kinase Domain-like Protein Executioner Domain. J.Med.Chem., 64, 2021
|
|
7NM4
| Solution structure of MLKL executioner domain in complex with a fragment | Descriptor: | (~{S})-1~{H}-benzimidazol-2-yl-(4-propan-2-ylphenyl)methanol, Mixed lineage kinase domain-like protein | Authors: | Ruebbelke, M, Bauer, M, Hamilton, J, Binder, F, Nar, H, Zeeb, M. | Deposit date: | 2021-02-23 | Release date: | 2021-09-22 | Last modified: | 2024-06-19 | Method: | SOLUTION NMR | Cite: | Discovery and Structure-Based Optimization of Fragments Binding the Mixed Lineage Kinase Domain-like Protein Executioner Domain. J.Med.Chem., 64, 2021
|
|
6ZVO
| Crystal structure of unliganded MLKL executioner domain | Descriptor: | BROMIDE ION, CHLORIDE ION, Mixed lineage kinase domain-like protein | Authors: | Fiegen, D, Bauer, M, Nar, H. | Deposit date: | 2020-07-27 | Release date: | 2020-12-23 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.371 Å) | Cite: | Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
6ZZ1
| Crystal structure of MLKL executioner domain in complex with a covalent inhibitor | Descriptor: | 7-(2-methoxyethoxymethyl)-1,3-dimethyl-purine-2,6-dione, Mixed lineage kinase domain-like protein | Authors: | Fiegen, D, Bauer, M, Nar, H. | Deposit date: | 2020-08-03 | Release date: | 2020-12-23 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.64 Å) | Cite: | Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis. Proc.Natl.Acad.Sci.USA, 117, 2020
|
|
2YKL
| Structure of human anti-nicotine Fab fragment in complex with nicotine-11-yl-methyl-(4-ethylamino-4-oxo)-butanoate | Descriptor: | FAB FRAGMENT, HEAVY CHAIN, LIGHT CHAIN, ... | Authors: | Tars, K, Kotelovica, S, Lipowsky, G, Bauer, M, Beerli, R, Bachmann, M, Maurer, P. | Deposit date: | 2011-05-27 | Release date: | 2011-11-16 | Last modified: | 2023-12-20 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Different Binding Modes of Free and Carrier-Protein-Coupled Nicotine in a Human Monoclonal Antibody. J.Mol.Biol., 415, 2012
|
|
2YK1
| Structure of human anti-nicotine Fab fragment in complex with nicotine | Descriptor: | (S)-3-(1-METHYLPYRROLIDIN-2-YL)PYRIDINE, FAB FRAGMENT, HEAVY CHAIN, ... | Authors: | Tars, K, Kotelovica, S, Lipowsky, G, Bauer, M, Beerli, R, Bachmann, M, Maurer, P. | Deposit date: | 2011-05-25 | Release date: | 2011-11-16 | Last modified: | 2023-12-20 | Method: | X-RAY DIFFRACTION (1.85 Å) | Cite: | Different Binding Modes of Free and Carrier-Protein-Coupled Nicotine in a Human Monoclonal Antibody. J.Mol.Biol., 415, 2012
|
|
1PFX
| PORCINE FACTOR IXA | Descriptor: | D-phenylalanyl-N-[(2S,3S)-6-{[amino(iminio)methyl]amino}-1-chloro-2-hydroxyhexan-3-yl]-L-prolinamide, FACTOR IXA | Authors: | Brandstetter, H, Bauer, M, Huber, R, Lollar, P, Bode, W. | Deposit date: | 1995-07-19 | Release date: | 1996-08-17 | Last modified: | 2013-02-27 | Method: | X-RAY DIFFRACTION (3 Å) | Cite: | X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc.Natl.Acad.Sci.USA, 92, 1995
|
|
1SMP
| CRYSTAL STRUCTURE OF A COMPLEX BETWEEN SERRATIA MARCESCENS METALLO-PROTEASE AND AN INHIBITOR FROM ERWINIA CHRYSANTHEMI | Descriptor: | CALCIUM ION, ERWINIA CHRYSANTHEMI INHIBITOR, SERRATIA METALLO PROTEINASE, ... | Authors: | Baumann, U, Bauer, M, Letoffe, S, Delepelaire, P, Wandersman, C. | Deposit date: | 1995-01-13 | Release date: | 1996-04-03 | Last modified: | 2011-07-13 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Crystal structure of a complex between Serratia marcescens metallo-protease and an inhibitor from Erwinia chrysanthemi. J.Mol.Biol., 248, 1995
|
|
1DB2
| CRYSTAL STRUCTURE OF NATIVE PLASMINOGEN ACTIVATOR INHIBITOR-1 | Descriptor: | PLASMINOGEN ACTIVATOR INHIBITOR-1 | Authors: | Nar, H, Bauer, M, Stassen, J.M, Lang, D, Gils, A, Declerck, P. | Deposit date: | 1999-11-02 | Release date: | 1999-11-10 | Last modified: | 2024-02-07 | Method: | X-RAY DIFFRACTION (2.7 Å) | Cite: | Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation. J.Mol.Biol., 297, 2000
|
|
6EQC
| Cryo-EM reconstruction of a complex of a binding protein and human adenovirus C5 hexon | Descriptor: | Hexon protein, scFv of 9C12 antibody | Authors: | Schmid, M, Ernst, P, Honegger, A, Suomalainen, M, Zimmermann, M, Braun, L, Stauffer, S, Thom, C, Dreier, B, Eibauer, M, Kipar, A, Vogel, V, Greber, U.F, Medalia, O, Plueckthun, A. | Deposit date: | 2017-10-12 | Release date: | 2018-02-07 | Last modified: | 2018-02-14 | Method: | ELECTRON MICROSCOPY (7.4 Å) | Cite: | Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun, 9, 2018
|
|
5OGI
| Complex of a binding protein and human adenovirus C 5 hexon | Descriptor: | 1,2-ETHANEDIOL, 1,4-DIETHYLENE DIOXIDE, 2-(N-MORPHOLINO)-ETHANESULFONIC ACID, ... | Authors: | Schmid, M, Ernst, P, Honegger, A, Suomalainen, M, Zimmermann, M, Braun, L, Stauffer, S, Thom, C, Dreier, B, Eibauer, M, Kipar, A, Vogel, V, Greber, U.F, Medalia, O, Plueckthun, A. | Deposit date: | 2017-07-13 | Release date: | 2018-02-07 | Last modified: | 2024-01-17 | Method: | X-RAY DIFFRACTION (2.8 Å) | Cite: | Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control. Nat Commun, 9, 2018
|
|
1QBO
| |
9FHE
| hKHK-C in complex with BI-9787 (pH 5.5) | Descriptor: | (2~{S})-3-[3-[[4-[bis(fluoranyl)methyl]-3-cyano-6-[(3~{S})-3-(dimethylamino)pyrrolidin-1-yl]pyridin-2-yl]amino]-4-methylsulfanyl-phenyl]-2-methyl-propanoic acid, Ketohexokinase | Authors: | Ebenhoch, R, Pautsch, A. | Deposit date: | 2024-05-27 | Release date: | 2024-09-04 | Method: | X-RAY DIFFRACTION (2.313 Å) | Cite: | Discovery of BI-9787, a potent zwitterionic ketohexokinase inhibitor with oral bioavailability. Bioorg.Med.Chem.Lett., 112, 2024
|
|
9FHD
| hKHK-C in fomplex with BI-9787 | Descriptor: | (2~{S})-3-[3-[[4-[bis(fluoranyl)methyl]-3-cyano-6-[(3~{S})-3-(dimethylamino)pyrrolidin-1-yl]pyridin-2-yl]amino]-4-methylsulfanyl-phenyl]-2-methyl-propanoic acid, Ketohexokinase, SULFATE ION | Authors: | Ebenhoch, R, Pautsch, A. | Deposit date: | 2024-05-27 | Release date: | 2024-09-04 | Method: | X-RAY DIFFRACTION (1.845 Å) | Cite: | Discovery of BI-9787, a potent zwitterionic ketohexokinase inhibitor with oral bioavailability. Bioorg.Med.Chem.Lett., 112, 2024
|
|
5G4M
| |
7PCD
| HER2 IN COMPLEX WITH A COVALENT INHIBITOR | Descriptor: | 1-[4-[4-[[3,5-bis(chloranyl)-4-([1,2,4]triazolo[1,5-a]pyridin-7-yloxy)phenyl]amino]pyrimido[5,4-d]pyrimidin-6-yl]piperazin-1-yl]-4-(3-fluoranylazetidin-1-yl)butan-1-one, Receptor tyrosine-protein kinase erbB-2 | Authors: | Bader, G. | Deposit date: | 2021-08-03 | Release date: | 2022-07-27 | Last modified: | 2024-01-31 | Method: | X-RAY DIFFRACTION (1.77 Å) | Cite: | Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling. Nat Cancer, 3, 2022
|
|
5G4O
| Crystal structure of the p53 cancer mutant Y220C in complex with a trifluorinated derivative of the small molecule stabilizer Phikan083 | Descriptor: | CELLULAR TUMOR ANTIGEN P53, N,N-dimethyl-1-[9-(2,2,2-trifluoroethyl)-9H-carbazol-3-yl]methanamine, ZINC ION | Authors: | Joerger, A.C, Bauer, M, Baud, M.G.J, Spencer, J. | Deposit date: | 2016-05-13 | Release date: | 2016-06-22 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (1.48 Å) | Cite: | Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of P53 Mutant Y220C Rescue Drugs. Acs Chem.Biol., 11, 2016
|
|
5G4N
| Crystal structure of the p53 cancer mutant Y220C in complex with a difluorinated derivative of the small molecule stabilizer Phikan083 | Descriptor: | 1-[9-(2,2-difluoroethyl)-9H-carbazol-3-yl]-N-methylmethanamine, CELLULAR TUMOR ANTIGEN P53, GLYCEROL, ... | Authors: | Joerger, A.C, Bauer, M, Jones, R.N, Spencer, J. | Deposit date: | 2016-05-13 | Release date: | 2016-06-22 | Last modified: | 2024-01-10 | Method: | X-RAY DIFFRACTION (1.35 Å) | Cite: | Harnessing Fluorine-Sulfur Contacts and Multipolar Interactions for the Design of P53 Mutant Y220C Rescue Drugs. Acs Chem.Biol., 11, 2016
|
|